Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets
A MAGNIFY-MS Substudy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 28, 2022
- Accepted in final form September 6, 2022
- First Published November 21, 2022.
Author Disclosures
- Heinz Wiendl, MD, PhD,
- Klaus Schmierer, MD, PhD,
- Suzanne Hodgkinson, MBBS, PhD,
- Tobias Derfuss, MD,
- Andrew Chan, MD,
- Finn Sellebjerg, PhD, MD,
- Anat Achiron, MD, PhD,
- Xavier Montalban, MD, PhD,
- Alexandre Prat, MD, PhD,
- Nicola De Stefano, MD, PhD,
- Frederik Barkhof, MD, PhD,
- Letizia Leocani, MD,
- Patrick Vermersch, MD, PhD,
- Anita Chudecka, MSc,
- Claire Mwape, PhD,
- Kristina H. Holmberg, PhD*,
- Ursula Boschert, PhD and
- Sanjeev Roy, MBBS, MD on behalf of MAGNIFY-MS Study Group
- Heinz Wiendl, MD, PhD,
(1) Abbvie (2) Alexion (3) Argenx (4) Bristol Myers Squibb/Celgene (5) Janssen (6) Merck (7) Novartis
NONE
(1) Alexion (2) Biogen (3) Bristol Myers Squibb (4) F. Hoffmann-La Roche Ltd. (5) Genzyme (6) Merck (7) Neurodiem (8) Novartis (9) Roche Pharma AG (10) TEVA (11) WebMD Global.
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) Bristol Myers Squibb (6) EMD Serono (7) Fondazione Cariplo (8) Gossamer Bio (9) Idorsia (10) Immunic (11) Immunovant (12) Janssen (13) Lundbeck (14) Merck (15) NexGen (16) Novartis (17) PSI CRO (18) Roche (19) Sanofi (20) the Swiss Multiple Sclerosis Society (21) UCB (22) Worldwide Clinical Trials
NONE
NONE
NONE
(1) Alexion (2) Amicus Therapeutics Inc. (3) Argenx (4) Biogen (5) CSL Behring (6) F. Hoffmann - La Roche (7) Genzyme (8) Merck KgaA (9) Novartis Pharma (10) Roche Pharma (11) UCB Biopharma
(1) Krankheitsbezogenes Kompetenznetz MS, Principal investigator, 2014-2020, (2) Deutsche Forschungsgesellschaft: WI1722/16-1 AOBJ:660106, Principal investigator, 2019-2022; SFB-TRR 128- A09, Principal investigator, 2012-2020; GZ: WI1722/17-1 AOBJ:668321, principal investigator, 2020-2023 (3) European Union, 779316, principal investigator,2018-2023
NONE
(1) Deutsche Myasthenie Gesellschaft e.V.
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus Schmierer, MD, PhD,
;(i) Novartis (ii) Merck KGaA (iii) EMD Serono (iv) Roche (v) GW Pharma
NONE
(i) Novartis, speaker honoraria (ii) Biogen, speaker honoraria (iii) Teva, speaker honoraria (iv) Merck KGaA, speaker honoraria (v) EMD Serono, speaker honoraria (vi) Sanofi-Genzyme, speaker honoraria (vii) Roche, speaker honoraria
MS Reports, editorial board, since Jun 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(i) National Institute of Health Research, Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership, (ii) Multiple Sclerosis Society of Great Britain & Northern Ireland, (iii) National Multiple Sclerosis Society (USA), (iv) Barts Charity, (v) Morris-Saady Charitable Trust
NONE
NONE
NONE
NONE
NONE
NONE
- Suzanne Hodgkinson, MBBS, PhD,
Commercial pharma MERCK Novartis Bayer Atara Biogen Roche
NONE
MERCK - Advisory boards, travel Novartis- Advisory boards, travel Biogen - Advisory boards, travel Roche - Advisory boards, travel Atara - Advisory boards, Travel
NONE
The role of cytokine IL-5 in antigen specific T cell tolerance
NONE
NONE
NONE
NONE
Invited to record some podcasts reviewing MS literature by Novartis.
NONE
Monitoring of activated Tcells in cladribine patients 75,0000 MerckC clinical trial funding by Biogen, Merck, Novartis, Sanofi, Atara
NH&MRC project grant 2013-2016
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Derfuss, MD,
Scientific advisory boards for (1) Biogen (2) Novartis (3) Genzyme (4) Merck (5) Bayer (6) Octapharma (7) GeNeuro (8) Roche (9) Actelion (10) Celgene (11) MedDay (12) Alexion
NONE
travel and speaker honoraria from (1) Biogen (2) Merck (3) Novartis (4) Genzyme (5) Roche
Member of the Editorial board of Plos One
NONE
NONE
My wife is an employee of Novartis.
Member of steering committee in clinical trials by Novartis, Merck, Mitsubishi Pharma, Roche and GeNeuro
(1) Biogen (2)Novartis (3) Merck (4) Genzyme (5) Roche
Member of the Executive board of ECTRIMS (non-profit entity)
NONE
(1) Novartis (2) Biogen (3) Roche (4) Alexion
(1)PI of a projected funded by the Swiss National Foundation
NONE
(1) Swiss MS Society
NONE
NONE
NONE
My wife owns shares from Novartis
NONE
NONE
- Andrew Chan, MD,
(1) Almirall (2) Actelion-Janssen (3) Alexion (4) Bayer (5) Biogen (6) Bristol Myers Squibb (7) Celgene (8) Genzyme (9) Merck (10) Novartis (11) Roche (12) Teva, all for Hospital Research funds
NONE
(1) Almirall (2) Actelion-Janssen (3) Alexion (4) Bayer (5) Biogen (6) Bristol Myers Squibb (7) Celgene (8) Genzyme (9) Merck (10) Novartis (11) Roche (12) Teva; travel and speaker honoraria, all for Hospital Research funds
Clinical and Translational Neuroscience (Editorial board) Topic editor, Journal of International medical Research, European Journal of Neurology (Associate Editor)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from Biogen, Genzyme, UCB, CSL Behring and Roche
(1) Schweizer Nationalfonds, Principle investigator, 2 years, (2) EU Horizon 2020, Principle Investigator 2 years, (3) EU Marie Curie Network, Principle Investigator 2 years, (4) University Bern Co-Pi
NONE
Swiss multiple sclerosis society, Co-PI, 2 years
NONE
NONE
NONE
NONE
NONE
NONE
- Finn Sellebjerg, PhD, MD,
Participation in advisory boards for Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi Genzyme.
NONE
Travel grants or speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva.
Section editor (immunology) for Multiple Sclerosis and Related Disorders since 2012
NONE
NONE
NONE
Member of steering committee for clinical trials for Merck and Roche. Consulting work for Novartis.
NONE
NONE
NONE
Research support from Biogen, Merck, Novartis, Roche, Sanofi Genzyme.
NONE
NONE
Grant support from: Danish Multiple Sclerosis Society, the Johnsen Foundation, Foundation for Research in Neurology, the Friis Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Anat Achiron, MD, PhD,
Participated in advisory boards related to clinical trials design, trial steering committees, and data and safety monitoring committees from Biogen, Bristol Myers Squibb, Novartis, Merck, Roche, and Sanofi-Genzyme, and received research support for investigator-initiated trials and MS patients' benefits activities from Bristol Myers Squibb, Biogen, Merck, Novartis, Roche, and Sanofi- Genzyme.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Montalban, MD, PhD,
(1) Actelion, (2) Alexion, (3) Biogen, (4) Bristol-Myers Squibb/Celgene, (5) EMD Serono, (6) Genzyme, (7) Hoffmann-La Roche, (8) Immunic, (9) Janssen Pharmaceuticals, (10) Medday, (11) Merck, (12) Mylan, (13) Nervgen, (14) Novartis, (15) Sanofi-Genzyme, (16) Teva Pharmaceutical, (17) TG Therapeutics
NONE
Travel to scientific meetings: (1) Actelion, (2) Alexion, (3) Biogen, (4) Bristol- Myers Squibb/Celgene, (5) EMD Serono, (6) Genzyme, (7) Hoffmann-La Roche, (8) Immunic, (9) Janssen Pharmaceuticals, (10) Medday, (11) Merck, (12) Mylan, (13) Nervgen, (14) Novartis, (15) Sanofi-Genzyme, (16) Teva Pharmaceutical, (17) TG Therapeutics, (18) Excemed, (19) MSIF and (20) NMSS.
Member of editorial boards: (1) Multiple Sclerosis Journal, (2) Journal of Neurology, (3) The International MS Journal, (4) Revista de Neurologia, (5) Therapeutic Advances in Neurological Disorders
NONE
NONE
NONE
(1) Biogen, (2) Celgene, (3) Merck, (4) Novartis, (5) Roche, (6) Sanofi-Genzyme and (7) Teva Pharmaceutical.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Vice-president, Multiple Sclerosis Foundation of Barcelona (FEM) and (2) President, Fundació Cemcat
NONE
NONE
NONE
NONE
NONE
NONE
- Alexandre Prat, MD, PhD,
Biogen, EMD Serono, Teva, Celgene, Sanofi, Roche, Novartis
NONE
None
(1) Multiple Sclerosis Journal, associate editor; (2) Cellular Immunology, associate editor (3) Brain, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1-CIHR 2-MSSC 3-PMSA 4-NMSS 5-Canada Research Chair
NONE
None
NONE
NONE
NONE
NONE
NONE
Expert Opinion to the Federal Court of Justice of Canada
- Nicola De Stefano, MD, PhD,
Prof. N. De Stefano serves on scientific advisory boards for Merck, Teva, Sanofi, Genzyme, Roche, Biogen, Immunic and Novartis Pharma AG
NONE
Travel expense refunds from Biogen Idec, Merck, Bayer- Schering AG, Teva, Sanofi, Genzyme, Roche, Biogen and Novartis Pharma AG
Editorial Advisory Board Member of Neurological Sciences
NONE
NONE
NONE
Biogen Idec, Merck, Sanofi, Genzyme, Roche, Immunic, Biogen and Novartis Pharma AG
Biogen Idec, Merck, Sanofi, Genzyme, Celgene, Roche, Immunic, Bristol-Meyers Squibb, Biogen and Novartis Pharma AG
NONE
NONE
NONE
NONE
NONE
Co-Funder of Siena Imaging s.r.l. Support from Italian MS society
NONE
NONE
NONE
NONE
NONE
NONE
- Frederik Barkhof, MD, PhD,
Biogen, Merck, Roche, Eisai, Merck, Prothena, Combinostics
NONE
None
Editorial board member for Radiology, Multiple Sclerosis Journal, Neuroradiology (section editor), Neurology
NONE
NONE
NONE
Novartis, Biogen, Roche, Janssen, IXICO
NONE
NONE
NONE
Image analysis in CONSONANCE study (Roche)
AMYPAD coordinator (IMI), NIHR-UCLH biomedical research centre
NONE
OCTOPUS study by the UK MS society
Founder and stock-owner of Queen Square Analytics LTD
NONE
NONE
NONE
NONE
NONE
- Letizia Leocani, MD,
(1) Merck KGaA
NONE
(1) Roche, travel support (2) Merck Serono, travel support
(1) European Journal of Neurology, Associate Editor, 2020, (2) Frontiers in Neurology, Associate Editor, 2018, (3) CLinical Neurophysiology Practice, Associate Editor, 2016, (4) Neurological Sciences, Associate Editor, 2018 (5) Neurophysiologie Clinique, Associate Editor, 2020
NONE
NONE
NONE
(1) Merck KGaA, (2) Roche, (3), Biogen, (4) Bristol-Meyer Squibb, (5) Almirall, (6) Janssen-Cilag
(1) Med-Ex
NONE
NONE
(1) Biogen, (2) Novartis, (3) Merck KGaA
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Vermersch, MD, PhD,
Serves on scientific advisory boards for (1) Sanofi, (2) Biogen, (3) Merck, (4) Teva, (5) Novartis, (6) Roche, (7) Imcyse, (8) Celgene (9) AB Science
NONE
(1) Biogen, travel and speaker honoraria; (2) Roche, travel and honoraria; (3) Novartis, honoraria; (4) Teva, travel and honoraria; (5) Sanofi-Aventis, honoraria; (6) Merck Serono, travel and honoraria (7) Celgene, travel and honoraria (8) AB Science (honoraria)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from (1) Merck, (2) Sanofi-Genzyme, (3) Roche
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Anita Chudecka, MSc,
None
NONE
None
NONE
NONE
NONE
(1)Employed at Cytel Inc., Statistician, 2019-today
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Claire Mwape, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kristina H. Holmberg, PhD*,
None
NONE
None
NONE
NONE
NONE
Currently an employee at Biogen Inc, MA, USA Previously an employee at EMD Serono, MA, USA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ursula Boschert, PhD and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sanjeev Roy, MBBS, MD on behalf of MAGNIFY-MS Study Group
None
NONE
None
NONE
NONE
NONE
Merck KGaA Senior Medical Director 7 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany and Brain and Mind Center, University of Sydney, Australia; The Blizard Institute (K.S.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience) (K.S.), The Royal London Hospital, Barts Health NHS Trust, UK; Ingham Institute for Applied Medical Research (S.H.), University of New South Wales Medicine, Sydney, Australia; Department of Neurology (T.D.), University Hospital Basel, Switzerland; Department of Neurology (Andrew Chan), Inselspital, Bern University Hospital, University of Bern, Switzerland; Danish MS Center (F.S.), Department of Neurology, Copenhagen University Hospital–Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine (F.S.), University of Copenhagen, Denmark; Multiple Sclerosis Center (A.A.), Sheba Academic Medical Center, Ramat Gan, Israel; Sackler School of Medicine (A.A.), Tel-Aviv University, Israel; Department of Neurology-Neuroimmunology (X.M.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain; Department of Neurosciences and CRCHUM (A.P.), Université de Montréal, QC, Canada; Department of Neurological and Behavioural Sciences (N.D.S.), University of Siena, Italy; Department of Radiology (F.B.), VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology (F.B.), London, UK; Experimental Neurophysiology Unit (L.L.), Vita-Salute San Raffaele University, Milan, Italy; Univ. Lille (P.V.), Inserm U1172 LilNCog, CHU Lille, FHU Precise, France; Cytel Inc (Anita Chudecka), Geneva, Switzerland; InScience Communications (C.M.), Springer Healthcare Ltd, Chester, UK; EMD Serono (K.H.H.), Billerica, MA; and Ares Trading SA (U.B., S.R.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
- Correspondence
Dr. Wiendl heinz.wiendl{at}ukmuenster.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.